Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > funny when someone rises concerns re eg funding which

<< Previous

Bullboard Posts

Next >>

Comment by JMark80on Jun 11, 2020 2:32pm

54 Views

Post# 31139726

RE:RE:RE:RE:funny when someone rises concerns re eg funding which

Why do you think it would take $6mm to get to phase 3, then another $10mm to finish phase 3. Could it be the $10mm included $6mm plus milestone payments and contingencies?

I said Golly to mock you, because it makes you sound like a 90 year old.

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale